ALX Oncology (ALXO) vs AN2 Therapeutics (ANTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed ALX Oncology (ALXO) over the past year, gaining 262.8% versus a loss of 40.1%. ALX Oncology is the larger company by market cap ($172.8 million vs $166.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | ANTX |
|---|---|---|
| Share price | $1.25 | $4.40 |
| Market cap | $172.85M | $166.04M |
| 1-day change | +5.93% | -5.98% |
| YTD return | +4.42% | +310.53% |
| 1-year return | -40.10% | +262.79% |
| 5-year return | -98.00% | — |
| EPS (TTM) | $-1.13 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $7.19 |
| 52-week low | $1.05 | $1.00 |
| Distance from 52-week high | -53.01% | -38.80% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.00% | +104.55% |
| Average volume | 1.04M | 240.21K |
| Shares outstanding | 138.28M | 37.74M |
| Employees | 48 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed ALXO by 302.9 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ALXO vs ANTX FAQ
Which is bigger, ALX Oncology or AN2 Therapeutics?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $166.04M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ALXO or ANTX?
ANTX returned +262.79% over the past 12 months, compared with -40.10% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and AN2 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.